Atara had been working with Pierre Fabre Laboratories in a bid to secure approval for Ebvallo in EBV+PTLD for U.S. patients who’ve received at least one prior therapy for their disease.
L’Ebvallo fait l’objet d’un accord de licence entre Pierre Fabre et Atara depuis octobre 2021. Le laboratoire français dispose des droits en Europe, au Moyen-Orient, en Afrique et dans d ...
Hosted on MSN2mon
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer CandidateTab-cel, the company’s novel T-cell immunotherapy, is already marketed in the EU under the brand name, Ebvallo, by Atara’s partner Pierre Fabre under an exclusive commercialization and license ...
“We will further narrow our focus on the future financial value of EBVALLO for the benefit of all stakeholders. Atara continues to productively engage with our partner Pierre Fabre Laboratories ...
Deuxième laboratoire dermo-cosmétique mondial et deuxième groupe pharmaceutique privé français, Pierre Fabre se met à la page de l'IA générative. Une prise de conscience initiée par l ...
Hosted on MSN2mon
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The DipAtara's partner, Pierre Fabre Laboratories ... noting the potential for substantial returns once the issues are resolved. EBVALLO received marketing authorization from the European Commission ...
Stay updated on market trends for ATRA. FDA halts Atara's EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre upon EBVALLO approval.
Tabelecleucel (tab-cel ® or Ebvallo ™) for Post-Transplant Lymphoproliferative ... eligible for significant milestone payments from Pierre Fabre upon FDA approval of the EBVALLO BLA and related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback